WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company's technology in its health system’s leading research facilities.
“Our hospital has a long history of innovation and research and is seen as one of the leading medical institutions across Latin America, including in the field of medical robotics. Being the first hospital in the Southern Hemisphere to implement CorPath GRX shows our continued dedication to finding the best possible treatments for our patients,” said Dr. Marcelo Franken, Head of Cardiology, Albert Einstein Jewish Hospital. “This partnership with Corindus is aligned with our vision of the future and will help our recently launched Center of Complex Cardiac Interventions to further our clinical research efforts as we continue to invest in the world’s leading technologies,” said Dr. Pedro Lemos, Head of Interventional Cardiology of the Hospital.
Recent data indicates that approximately 90,000 percutaneous coronary intervention (PCI) procedures are performed each year in Brazil's public health system, a number that increases at a rate of approximately five to seven percent every year. A similar number of privately insured patients undergo PCI procedures in Brazil annually. Additionally, cardiovascular disease is the leading cause of death in Brazil, accounting for 28% of deaths annually. The hospital will implement the system in a clinical research capacity to evaluate the safety and effectiveness of robotics and to support efforts to obtain future regulatory approval by the Brazilian Health Regulatory Agency. Dr. Sidney Klajner, president of the Sociedade Beneficente Israelita Brasileira Albert Einstein, stated, “We are thrilled to, once more, contribute to leading breakthroughs in the health system in the country. Adding Corindus to our portfolio is one of the steps we take towards the excellence that we treasure here at Einstein. The access to robotic procedures in Brazil is limited, not only in the public health system, but in the private, and as one of the precursors in the innovation and specifically in robotics, Einstein is committed to bringing new techniques and systems to bring about this scenario.”
“The demand for robotics based medical procedures in South America is significant and Corindus is proud to partner with one of Brazil’s leading healthcare institutions to introduce this technology,” said Mark Toland, President and Chief Executive Officer of Corindus. “This latest installation marks yet another key milestone in Corindus’ global expansion, which over the past few months includes France, Japan and now Brazil. We are excited about the growing adoption of vascular robotics in South America and across the globe.”
To learn more about Corindus and CorPath GRX, please visit www.corindus.com.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.
About Sociedade Beneficente Israelita Brasileira Albert Einstein
Sociedade Beneficente Israelita Brasileira Albert Einstein is a non-profit civil organization. With more than 60 years of history, it works in the areas of health assistance, education, research, innovation and social responsibility. It has 12,900 employees, 9,000 doctors and is based in São Paulo. Einstein has the Certificate of Benefit Entity of Social Assistance and is a Social Health Organization to act in the render of services in the Unified Health System (SUS). Its commitment to the broad development of the health system translates into the opportunity for improvement and the construction of new models of work adjusted to the current challenges. Einstein participates in national and international discussion forums, and actively takes part in joint initiatives with the public sector, regulatory agencies, hospitals, health plan operators and sector entities for the development of the Brazilian health system.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Examples of such statements include statements regarding or such as:
- That Albert Einstein Jewish Hospital (the "Hospital") will continue to uphold its standing by leveraging the technology in the health system’s leading research facilities.
- That the Hospital's partnership with Corindus will allow the Hospital's team to help further its clinical research efforts.
- That the Hospital will implement the system in a clinical research capacity to evaluate the safety and effectiveness of robotics.
- Future regulatory approval of the CorPath GRX System by the Brazilian Health Regulatory Agency.
- That the Hospital's implementation of the CorPath GRX System will be a leading breakthrough in the health system of Brazil.
- That the Hospital is committed to bringing new techniques and systems to market.
- The growing adoption of vascular robotics in South America and across the globe.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries, including for stroke and other neurovascular interventions; the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.